Stocktoria
Nuvectis Pharma, Inc. NVCT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2022-02-04
Chart by TradingView
3/9
Piotroski F — financial health
-10.83
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$27.6M | -$19.8M | -$22.9M | -$19.2M | -$12.9M |
| Net income | -$26.4M | -$19.0M | -$22.3M | -$19.1M | -$12.9M |
| Operating cash flow | -$16.0M | -$12.2M | -$16.0M | -$13.6M | -$9.5M |
| Total assets | $31.7M | $18.6M | $19.2M | $20.4M | $6.7M |
| Total liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M |
| Shareholders' equity | $18.4M | $9.7M | $12.2M | $14.2M | -$11.0M |
| Ratios | |||||
| Return on assets | -83.4% | -102.1% | -116.0% | -93.5% | -193.6% |
| Return on equity | -143.6% | -195.6% | -182.4% | -134.2% | 117.1% |
| Current ratio | 2.38 | 2.09 | 2.75 | 3.30 | 2.41 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -10.83 (distress)
- Working capital / assets 0.581
- Retained earnings / assets -3.144
- EBIT / assets -0.87
- Equity / liabilities 1.385
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001875558 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.